HDL and ASCVD

Hongtu Cui; Qian Du

doi:10.1007/978-981-19-1592-5_8

HDL and ASCVD

Adv Exp Med Biol. 2022:1377:109-118. doi: 10.1007/978-981-19-1592-5_8.

Authors

Hongtu Cui¹, Qian Du²

Affiliations

¹ Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing, China.
² Department of Cardiology, Guangzhou Red Cross Hospital, Medical College, Jinan University, Guangzhou, China. duqian1213@126.com.

PMID: 35575924
DOI: 10.1007/978-981-19-1592-5_8

Abstract

In this chapter, we summarize the relationship between circulating high-density lipoprotein (HDL) and atherosclerotic cardiovascular disease (ASCVD). HDL acts in many types of cells, such as endothelial cell, macrophage, T lymphocyte, etc. Recently, novel HDL-related therapies have been developed to treat ASCVD.

Keywords: Atherosclerotic cardiovascular disease (ASCVD); High-density lipoprotein (HDL); Molecular mechanism.

MeSH terms

Atherosclerosis* / therapy
Cardiovascular Diseases* / therapy
Humans
Lipoproteins, HDL
Risk Factors

Substances

Lipoproteins, HDL